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Purpose: To evaluate the cytotoxic effect of triamcinolone acetonide (TA) on cultured human trabecular meshwork (TM)
cells.
Methods: TA (0.1 mg/ml, 1 mg/ml) or the vehicle (benzyl alcohol, 0.0025%, 0.025%) was added to human TM cell
cultures on day 0 and collected subsequently on day 1, 3, or 5. The amount of cell proliferations with or without TA
treatment  was  measured  using  the  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylterazolium  bromide  (MTT)  assay.  All
samples were read in triplicate (n=4 in all cases). By using real-time quantitative polymerase chain reaction (PCR), gene
expression levels of c-fos, c-jun, caspase-3, c-myc, and p53 were determined after TA treatments at 0 min, 10 min, 20
min, 30 min, 50 min, 80 min, 2 h, 12 h, 24 h, and 48 h. Unpaired t-test was used to test the drug and concentration effects
of TA, ANOVA was used to test the time effects of TA, and the Bonferroni test was used to correct multiple comparisons.
Apoptosis of TM cells as a result of TA treatment were assessed by the terminal uridyl nick end labeling (TUNEL) assay.
Results: Both concentrations of TA caused a significant reduction in the number of human TM cells as early as day 1 and
across five days of the treatment period. Significantly increased expressions of c-jun, c-fos, c-myc, p53, and caspase 3
were observed at different time points after both 0.1 mg/ml and 1 mg/ml TA treatment. Significantly increased apoptotic
cells were observed after TA treatment for three days.
Conclusions: Our results showed that TA was cytotoxic to human TM cells in culture and the presence of TA caused
apoptotic cell death. It gave evidence that the underlying mechanism of TA caused ocular hypertension and may be
associated with necrosis and apoptosis of the TM cells.
Triamcinolone  acetonide  (9α-fluoro-16α-
hydroxyprednisolone,  TA)  is  commonly  used  through
intravitreal injections (IVTA) for macular diseases such as
uveitis [1,2], macular edema secondary to retinal vascular
disease [3,4], intraocular proliferations such as proliferative
vitreoretinopathy [5], and choroidal neovascularization from
age-related macular degeneration [6]. IVTA provides a direct
route to delivering the drug to the tissue cells of the posterior
segment. However, adverse events associated with the use of
IVTA have also been reported including intraocular pressure
(IOP)  elevation,  pseudoendophthalmitis,  endophthalmitis,
and cataractogenesis [7–9]. However, in rabbits, IVTA caused
relatively  little  or  no  retinal  toxicity  after  seven  days,
according to electroretinography [10]. Two recent reports also
revealed no electroretinographic or histological disruptions to
the rabbit retina after 28 days and 12 weeks [11,12].
One major side effect of IVTA is the induced elevation
of  IOP.  A  dosage  of  25  mg  led  to  a  secondary  ocular
hypertension in about 50% of the treated eyes, and the rise of
IOP was reversible around six months after the injection [3].
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Meta-analysis of a series of 272 patients showed that 20 mg
IVTA caused IOP elevation after one week, before subsiding
to the baseline level after eight to nine months [13]. Another
case series of 43 patients received a lower dose of 4 mg IVTA
and  there  was  no  effect  on  IOP  within  seven  days  [14].
Although the intraocular concentration of TA may fall below
the therapeutic range before 90 days, persistence of even a
trace  amount  may  lead  to  prolonged  ocular  hypertension
occasionally seen in some patients [15]. The human trabecular
meshwork  (TM)  in  the  chamber  angle  accounts  for  most
aqueous outflow resistance in the anterior chamber of the
human eye and participates in the regulation of intraocular
pressure. It is believed that the interplay between the TM cells
and the surrounding extracellular matrix is responsible for
maintaining the resistance necessary for the preservation of
the  aqueous  outflow  pathway  [16].  Like  many  other
corticosteroids, TA might affect the TM structural framework,
inhibit protease activities, or increase protein expression that
causes disruption of the aqueous outflow [17]. Since TM cells
are in constant contact with the aqueous humor, TA in the
aqueous humor may have direct biologic effects on the TM
tissue cells. We have found cytotoxicity caused by TA on
photoreceptors and retinal pigment epithelial (RPE) cells in
culture [18]. TA also decreased the expression of vascular
endothelial growth factor, an angiogenic agent, but increased
expression  of  the  angiogenic  inhibitor,  pigment  epithelial
derived factor, in both ARPE19 and human umbilical vein
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105endothelial cells [19]. Recently, we found the presence of TA
in the aqueous humor of rabbits given 12 mg IVTA [20]. The
TA presence in the aqueous humor of patients given IVTA
was inconsistent [21]. Deposition of the extracellular matrix
was likely to occur in two patients given 4 mg IVTA [22]. In
this study, we examined whether TA causes toxic and stress
responses of cultured human TM cells.
METHODS
Trabecular  meshwork  cell  culture  and  triamcinolone
acetonide treatment: A human trabecular meshwork cell line,
established from trabecular specimens obtained postmortem
from a patient with no personal or family history of glaucoma
[23],  was  courteously  provided  by  Dr.  Thai  Nguyen,
University of California San Francisco (San Francisco, CA).
Cell  culture  reagents,  fetal  bovine  serum  (FBS),
dimethylsulfoxide  (DMSO),  penicillin  G,  streptomycin,
phosphate-buffered saline (PBS), Dulbecco’s Modified Eagle
Media (DMEM), and trypsin were purchased from Invitrogen
Co. (Carlsbad, CA). Containers were from Corning Glass
(Acton, MA). TM cells were propagated in DMEM containing
10% FBS, 100 U/ml penicillin G, and 100 μg/ml streptomycin
sulfate. TM cell suspensions with cell volume of 1×104 were
seeded onto 100×20 mm tissue culture plates. The culture was
maintained in a humidified 5% CO2 environment at 37 °C. All
cells  within  the  same  23rd  passage  were  grown  to  80%
confluence for TA treatment. The cultures of TM cells with
80% confluence were adapted into fresh culture medium 12 h
before the addition of drugs. TA (Kenacort-A, Bristol-Myers-
Squibb, New York, NY) was serially diluted in a culture
medium to appropriate concentrations. The concentrations
used were derived from the known concentrations used in
experimental  and  clinical  settings  [4,18].  0.1  mg/ml  TA
contained 0.0025% benzyl alcohol (Sigma-Aldrich, Munich,
Germany) and 1 mg/ml TA contained 0.025% benzyl alcohol.
TA  (0.1  mg/ml,  1  mg/ml)  or  the  vehicle  benzyl  alcohol
(0.0025%, 0.025%) were well mixed and then added to the
TM cells.
MTT-cell  proliferation  assay:  The  amount  of  cell
proliferations  was  determined  using  the  1-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide
(MTT) assay. Cells were washed with PBS. MTT at 0.5 mg/
ml in a serum-free medium was then added to the cultures and
incubated for 3 h at 37 °C in a 5% CO2 environment. Formazan
extraction was performed with isopropanol, and the quantity
was  determined  colorimetrically  by  using  a
spectrophotometer  Powerwave  XS  at  λ=570  nm  with  the
correction  of  interference  at  690  nm.  All  four  replicated
samples per group were read in triplicate. The MTT assay was
performed  one,  three,  and  five  days  after  the  initial  TA
exposure. The results were expressed as units of absorbance
of MTT at 570 nm ±SD.
Gene expression study: The TM cells after exposure to TA or
the vehicle benzyl alcohol were collected at 0 min, 10 min, 20
min, 30 min, 50 min, 80 min, 2 h, 12 h, 24 h, and 48 h for RNA
extraction and real-time quantitative PCR (RT-qPCR). Every
time  point  was  measured  in  triplicate.  Total  RNA  was
extracted with RNeasy Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. Briefly, cells were
lysed  in  a  lysis  buffer  containing  1%  β-mercaptoethanol
(Sigma, St. Louis, MO) and then passed through a separation
column  (QIAShredder;  Qiagen).  RNA  samples  were
quantified  with  the  NanoDrop®  ND-1000  (NanoDrop
Technologies, Wilmington, DE), and 500 ng of total RNA was
used for reverse-transcription with 3 μg/μl random primer
p[dN]6 (Roche Diagnostics, Mannherim, Germany) and a
reverse transcriptase kit with a RNase inhibitor (Superscript
III  Reverse  Transcriptase  Kit  and  RNase  OUT  inhibitor;
Invitrogen).
The amount of cDNA corresponding to 25 ng of RNA
was selected and amplified with the primer pairs as previously
reported [9]. The sequences of intron-spanning primers were
as follows: GAPDH forward, 5′-GAA GGT GAA GGT CGG
AGT-3′ and reverse, 5′-GAA GAT GGT GAT GGG ATT
TC-3′; c-jun forward, 5′-GTG ACG GAC TGT TCT ATG
ACT G-3′ and reverse, 5′-GGG GGT CGG CGT GGT GGT
GAT G-3′; c-fos forward, 5′-AGA CAG ACC AAC TAG
AAG ATG A-3′ and reverse, 5′-AGC TCT GTG GCC ATG
GGC CCC-3′; caspase 3 forward, 5′-TAT TCT TGG GGA
AAT TCA AAG GAT-3′ and reverse, 5′-AAA GTA GCG
TCA AAG GAA AAG GAC-3′; p53 forward, 5′-TTG CCG
TCC CAA GCA ATG GAT GA-3′ and reverse, 5′ΤCT GGG
AAG GGA CAG AAG ATG AC-3′. RT-qPCR was performed
using SYBR Green PCR master mix (BioRad Laboratories,
Figure 1. Phase-contrast micrographs showing human trabecular
meshwork cells in 0.1 mg/ml TA (triamcinolone acetonide). In the
presence of 0.1 mg/ml TA, a large number of randomly distributed
TA particles could be seen on the top of the TM cells. Compared to
no  treatment  and  0.0025%  benzyl  alcohol  treatment,  there  was
progressive reduction of cell numbers, and the TM cells became more
oval and shrank after 0.1 mg/ml TA treatment. Scale bar: 50 μm.
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106Heracles,  CA).  ABI  PRISM  7000®  Sequence  Detection
System was used for real-time PCR (Applied Biosystems,
Foster City, CA). The thermocycler parameters were 95 °C
for 2 min followed by 40 cycles of 95 °C for 15 s and 60 °C
for 1 min. The relative quantification was normalized to the
GAPDH  expression  level.  The  mean  Ct  value  (threshold
cycle, cycle at which the increase in signal associated with
exponential growth of PCR product was first detected) of the
TA-treated sample was compared to that of the untreated
control sample using the Ct value of GAPDH as an internal
control. ΔCt was the difference in Ct values derived from the
target  gene  (in  each  sample  assayed)  and  GAPDH  while
ΔΔCt represented the difference between the paired samples.
The n-fold differential ratio was expressed as 2-ΔΔCt. All data
were expressed as mean±SD.
Detection for apoptosis: The TM cells were examined for
apoptosis 12 h as well as one, three, and five days after TA
(0.1 and 1 mg/ml) and vehicle treatment (benzyl alcohol,
0.0025%, 0.025%). The cells were fixed and permeabilized.
Apoptosis was determined using the terminal uridyl nick end
labeling (TUNEL) in situ cell death detection TMR kit using
Figure 2. Proliferation of human trabecular meshwork cells in the
presence of various concentrations of triamcinolone acetonide and
over a five-day treatment period. A: The asterisk indicates that both
concentrations of TA caused significant reduction in the number of
TM cells as early as day 1 and across 5 days of the treatment period
(p<0.01). The double asterisk means that there was a significant
difference in the number of TM cells between 0.025% and 0.0025%
benzyl alcohol in the culture (p<0.005). B: After eliminating the
benzyl alcohol effect, there was no significant difference in cell
proliferation between 0.1 mg/ml TA and 1 mg/ml TA one day after
treatment  (p=0.058)  while  a  significant  difference  in  cell
proliferation was observed between the two concentrations of TA
treatment on day 3 (p=0.003) and on day 5 (p<0.0005).
terminal  uridyl  nick  end  labeling  (Roche  Diagnostics,
Mannherim, Germany) according to the supplier's protocol.
After nuclear staining by DAPI, the samples were examined
by  fluorescence  microscopy  (DMRB;  Leica,  Wetzlar,
Germany)  equipped  with  the  Spot  RT  color  system
(Diagnostic Instruments, Sterling Heights, MI). The apoptosis
percentage due to TA was the apoptotic TM cell number
divided by the total TM cell number after adjustment of the
vehicle (benzyl alcohol) effect.
Statistical analysis: Unpaired t-test was used to test the drug
and concentration effects of TA whereas ANOVA was used
to test the time effect of TA. The Bonferroni test was applied
to correct multiple comparisons. p<0.05 was considered to be
statistically significant.
RESULTS
Cytotoxicity  of  triamcinolone  acetonide  in  trabecular
meshwork cells: In the presence of 0.1 mg/ml TA, a large
number of randomly distributed TA particles could be seen on
top  of  the  TM  cells  (Figure  1),  which  did  not  show
morphological changes under light microscopy. When the
concentration was increased to 1 mg/ml, no usable images
could  be  obtained  because  the  entire  field  of  view  was
virtually  covered  by  TA  particles.  The  MTT  experiments
showed that both concentrations of TA caused a significant
reduction in the number of TM cells as early as day 1 and
throughout  the  five-day  study  period  (Figure  2A).  After
eliminating the benzyl alcohol effect, there was no significant
difference in cell proliferation between the two concentrations
of TA after three days (p=0.003) and five days (p<0.0005;
Figure 2B). At 1 mg/ml, TA caused a significant reduction in
the number of TM cells on day 3 (p<0.0005) and on day 5
(p<0.0005)  (Figure  2B).  At  0.1  mg/ml,  TA  caused  a
significant reduction in the number of TM cells between day
1 and day 3, and there was a significant increase between day
3 and day 5 (p=0.018; Figure 2B). There was significant
interaction  between  the  concentration  and  time  effects
(p<0.0005).
Gene expression study: For all five genes investigated in the
present study including c-jun, c-fos, c-myc, p53, and caspase
3, the mRNA expression levels were significantly elevated in
the TA-treated TM cells compared to corresponding benzyl
alcohol-treated TM cells. However, except for p53, there were
significantly  different  gene  expressions  of  c-jun,  c-fos,  c-
myc, and caspase 3 between 0.025% and 0.0025% benzyl
alcohol  treatment  (Table  1,  Figure  3).  Therefore,  we
eliminated the benzyl alcohol effect by subtracting the gene
expression value of each gene induced by benzyl alcohol from
that induced by TA when we analyzed the concentration and
time effects of TA treatment (Figure 3).
For c-jun, the change in gene expression peaked at 20 min
when TM cells were treated with 1 mg/ml TA and the change
kept a significant increase between 10 min and 30 min. When
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107TM cells were treated with 0.1 mg/ml TA, c-jun expression
peaked at 50 min and kept significantly increasing between
10  min  and  12  h.  The  changes  in  gene  expression  were
concentration dependent between the 10 min-12 h interval.
Between 10 and 20 min, the c-jun expression change was
higher  for  1  mg/ml  TA  treatment.  However,  the  c-jun
expression change was higher for 0.1 mg/ml TA treatment
between 30 min and 12 h (Figure 3A).
For c-fos, the change in expression peaked at 10 min when
TM cells were treated with 1 mg/ml TA, and the change kept
significant elevation between 10 min and 80 min. When TM
cells were treated with 0.1 mg/ml TA, there was no significant
change  in  gene  expression  across  various  time  points
(p>0.05).  When  compared  to  1  mg/ml  TA  treatment,  the
changes in gene expression were higher for 0.1 mg/ml TA
treatment between 20 min and 30 min. (Figure 3B).
For c-myc, the change in expression peaked at 30 min and
50  min  for  0.1  mg/ml  TA  and  1  mg/ml  TA  treatment,
respectively. The gene expression change kept a significant
increase between 10 min and 2 h for both TA concentrations.
When compared to 1 mg/ml TA treatment, the change in gene
expression was higher for 0.1 mg/ml TA treatment at 10 min,
30 min, 80 min, and 48 h (Figure 3C).
For caspase 3, the change in gene expression for both
concentrations  of  TA  maintained  a  significant  increase
between 50 min and 48 h. When compared to 0.1 mg/ml TA,
TABLE 1. DRUG EFFECTS OF GENE EXPRESSION OF C-JUN, C-FOS, C-MYC, CASPASE 3 AND P53
Gene Treatment 0 min 10 min 20 min 30 min 50 min 80 min 2 h 12 h 24 h 48 h
c-jun 0.025% BA
versus
0.0025% BA
0.88 0.051 0.003 <0.0005 0.003 0.009 0.105 0.002 0.602 0.059
c-jun 0.1 mg/ml TA
versus
0.0025% BA
0.886 <0.0005 <0.0005 <0.0005 <0.0005 0.004 0.003 0.001 0.073 0.571
c-jun 1 mg/ml TA
versus
0.025% BA
0.891 <0.0005 <0.0005 0.001 0.452 0.051 <0.0005 0.361 0.075 0.080
c-fos 0.025% BA
versus
0.0025% BA
0.883 <0.0005 <0.0005 <0.0005 <0.0005 0.001 0.274 0.011 0.044 0.029
c-fos 0.1 mg/ml TA
versus
0.0025% BA
0.960 <0.0005 <0.0005 <0.0005 0.149 0.423 0.368 0.114 0.358 0.969
c-fos 1 mg/ml TA
versus
0.025% BA
0.660 <0.0005 0.002 <0.0005 <0.0005 0.002 0.245 0.933 0.607 0.072
c-myc 0.025% BA
versus
0.0025% BA
0.715 0.090 0.490 0.005 <0.0005 0.461 0.152 0.060 0.070 0.006
c-myc 0.1 mg/ml TA
versus
0.0025% BA
0.596 0.005 0.004 <0.0005 <0.0005 0.001 0.005 0.005 0.070 0.003
c-myc 1 mg/ml TA
versus
0.025% BA
0.814 0.804 0.005 0.001 <0.0005 0.442 0.008 0.007 0.065 0.081
caspase 3 0.025% BA
versus
0.0025% BA
0.902 0.683 0.089 0.070 1.000 0.041 0.154 0.024 0.099 0.033
caspase 3 0.1 mg/ml TA
versus
0.0025% BA
1.000 0.054 0.114 0.024 0.04 0.01 0.001 <0.0005 0.002 <0.0005
caspase 3 1 mg/ml TA
versus
0.025% BA
0.692 0.675 0.087 0.027 0.006 0.001 <0.0005 <0.0005 0.002 <0.0005
p53 0.025% BA
versus
0.0025% BA
0.305 0.21 0.709 0.516 0.152 0.057 0.057 0.51 0.189 0.718
p53 0.1 mg/ml TA
versus
0.0025% BA
0.678 0.067 0.059 0.25 0.003 0.001 <0.0005 <0.0005 <0.0005 <0.0005
p53 1 mg/ml TA
versus
0.025% BA
0.219 0.065 0.026 0.1 0.001 0.001 <0.0005 0.007 <0.0005 <0.0005
The gene expressions of all five genes were significantly elevated in the TA-treated TM cells compared to corresponding benzyl
alcohol-treated TM cells. However, except for p53, there were significantly different gene expressions of c-jun, c-fos, c-myc
and caspase 3 between 0.025% and 0.0025% benzyl alcohol treatment. The numbers are the p values for the drug effects of gene
expressions. BA indicates benzyl alcohol.
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108Figure 3. Changes in gene expression of
c-jun, c-fos, c-myc, caspase 3, and p53
after triamcinolone acetonide treatment.
A: For 1 mg/ml TA, the change of c-jun
expression  peaked  at  20  min  and  the
change  kept  a  significant  increase
between 10 min and 30 min. For 0.1 mg/
ml TA, c-jun expression peaked at 50
min  and  kept  significantly  increasing
between 10 min and 12 h. The changes
in gene expression were concentration
dependent  between  the  10  min-12  h
interval. Between 10 and 20 min, the c-
jun expression change was higher for 1
mg/ml TA treatment. However, the c-
jun expression change was higher for
0.1 mg/ml TA treatment between 30 min
and 12 h. B: For 1 mg/ml TA, the change
of c-fos expression peaked at 10 min and
the  change  kept  significant  elevation
between 10 min and 80 min. For 0.1 mg/
ml TA, there was no significant change
in gene expression across various time
points (p>0.05). Compared to 1 mg/ml
TA,  the  changes  in  gene  expression
were higher for 0.1 mg/ml TA treatment
between  20  min  to  30  min.  C:  The
change of c-myc expression peaked at
30 min and 50 min for 0.1 mg/ml TA and
1  mg/ml  TA  treatment,  respectively.
The  gene  expression  change  kept  a
significant increase between 10 min and
2  h  for  both  TA  concentrations.
Compared to 1 mg/ml TA, the change in
gene expression was higher for 0.1 mg/
ml TA treatment at 10 min, 30 min, 80
min and 48 h. D: The change of caspase
3 expression for both concentrations of
TA  maintained  a  significant  increase
between 50 min and 48 h. Compared to
0.1 mg/ml TA, the change was higher
for 1 mg/ml TA treatment only at 50
min. E: The change of p53 expression
for both concentrations of TA increased
significantly from 50 min to 48 h. The
change  in  gene  expression  was
concentration  dependent  between  2  h
and 48 h. The expression change was
greater for 1 mg/ml TA between 2 h and
12 h while the change was greater for 0.1
mg/ml between 24 h and 48 h. Dotted
lines represent initial gene expression
levels  before  eliminating  benzyle
alcohol (BA) effect from TA. Solid lines
represent  subtracted  gene  expression
levels after eliminating BA effect from
TA.
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109the change in gene expression was higher for 1 mg/ml TA
treatment only at 50 min (Figure 3D).
For p53, the change in expression for both concentrations
of TA increased significantly from 50 min to 48 h. The change
in gene expression was concentration dependent between 2 h
and 48 h. The expression change was greater for 1 mg/ml TA
between 2 h and 12 h while the expression change was greater
for 0.1 mg/ml TA between 24 h and 48 h (Figure 3E).
Apoptosis of trabecular meshwork cells after triamcinolone
acetonide  treatment:  Apoptotic  nuclei  of  TM  cells  were
detected  12  h  as  well  as  one,  three,  and  five  days  after
treatment by both 0.1 mg/ml and 1 mg/ml TA (Figure 4,5).
Significantly  increased  number  of  apoptotic  cells  were
observed at both TA concentrations at day 3 and day 5 (Figure
6). Compared to 0.1 mg/ml TA treatment, the apoptotic TM
cells were significantly increased five days after 1 mg/ml TA
treatment.
DISCUSSION
Results of the present study showed that TM cells exposed to
TA exhibit reduced cell proliferation and increased expression
of  genes  involved  in  stress  and  apoptosis.  In  view  of  a
significant difference in the number of TM cells between
different concentrations of benzyl alcohol given to the culture,
we eliminated the benzyl alcohol effect when we analyzed the
concentration  and  time  effects  of  TA  treatment.  Benzyl
Figure  4.  Apoptotic  trabecular  meshwork  cells  after  0.1  mg/ml
triamcinolone acetonide treatment. Apoptotic nuclei of TM cells
were detected 12 h as well as 1, 3, and 5 days after 0.1 mg/ml TA
treatment. The slide was viewed with two filters. Stain red was
viewed using a fluorescein filter to visualize end-labeled cells. Stain
blue  was  viewed  with  a  DAPI  filter  to  visualize  the  entire  cell
population. Scale bar: 50 μm.
alcohol has been reported to cause a reduction in relative
bodyweight, histopathologic lesion, and neurotoxicity [24].
Since benzyl alcohol is a vehicle of TA, both may cause
cytotoxicity to TM cells after intraocular injection of TA.
Detailed  statistical  analysis  of  the  initial  differential
expressions of all five studied genes (Figure 3, dotted lines)
revealed that significant differences persisted over several
time points for all the genes (Table 1). There was also a
difference in expression between 0.0025% and 0.025% benzyl
alcohol.  Therefore,  the  effects  of  benzyl  alcohol  were
subtracted from the total effects of TA in benzyl alcohol
(Figure 3, solid lines) which subsequently showed the sole
effects of TA on the gene expressions.
It is known that in patients with glaucoma, a significant
loss of TM cells occurs with increasing age. The cell depletion
may lead to disintegration and loss of the trabecular beams,
and the change of cell activities may adversely affect aqueous
outflow, causing IOP elevation [25,26]. Whereas the changes
in  MTT  absorbance  in  this  study  indicated  the  degree  of
necrosis,  the  gene  expression  data  showed  the  extent  of
apoptosis of TM cells in the presence of TA. Apoptosis has a
critical role in development, homeostasis, wound healing, and
pathophysiology of diseases. It has been implicated in these
processes in the retina, lens, cornea, TM, optic nerve, and the
central nervous system pathways that contribute to vision
[27]. Apoptosis pathways are not only stimulus-specific but
Figure  5.  Apoptotic  trabecular  meshwork  cells  after  1  mg/ml
triamcinolone acetonide treatment. Apoptotic nuclei of TM cells
were detected 12 h as well as 1, 3, and 5 days after 1 mg/ml TA
treatment. The slide was viewed with two filters. Stain red was
viewed using a fluorescein filter to visualize end-labeled cells. Stain
blue  was  viewed  with  a  DAPI  filter  to  visualize  the  entire  cell
population. Scale bar: 50 μm.
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110also  cell-type  specific.  Low  concentrations  of  chemical-
induced oxidative stress can elevate gene expressions of c-
jun and c-fos, which protect the cells against toxic insult and
enhance cell survival whereas high concentrations can lead to
apoptosis with the activation of the caspase-3 pathway [28].
Similar events might have been observed here. Significant
increases in c-fos and c-jun expressions were found early in
1 mg/ml TA treatment, but the duration was longer in 0.1 mg/
ml TA treatment (Figure 3A,B). Recently, c-jun was found
upregulated in glaucoma and optic nerve transaction models
[29], providing evidence of the involvement of c-jun NH2-
terminal  kinase  as  a  signaling  molecule  and  of  the
participation of tumor necrosis factor alpha in glaucoma.
The expression of caspase 3 was higher in 1 mg/ml TA
but  only  significantly  different  at  50  min  (Figure  3D).
Meanwhile, caspase 3 was upregulated for the three types of
cultured human cell lines tested for TA effects, TM, ARPE19,
and SVG [18], showing a cellular sensitivity of these cultured
cells on caspase 3. It also indicated that caspase 3 has a major
role in TA stimuli.
c-myc is a multifaceted protein that regulates the cell
cycle  and  cell  growth,  enhances  genomic  instability,  and
stimulates angiogenesis, cell transformation, and apoptosis
[30,31]. The main physiologic function of p53 is thought to
Figure 6. Apoptosis percentage of the trabecular meshwork cells by
0.1  mg/ml  and  1  mg/ml  triamcinolone  acetonide  treatment.  The
apoptosis  percentage  for  TA,  which  was  the  apoptotic  TM  cell
number divided by the total TM cell number, was adjusted by benzyl
alcohol. The asterisk indicates that significantly increased apoptotic
cells  were  observed  with  both  TA  treatment  on  days  3  and  5
compared to 12 h. The sharp (hash mark) means that when compared
to 0.1 mg/ml TA treatment, the number of the apoptotic TM cells
was significantly increased with 1 mg/ml TA treatment on day 5.
be a cell cycle regulator at the G1 checkpoint and an inductor
of apoptosis [26]. We found both c-myc and p53 upregulated
by TA. However, compared to c-myc, the change in gene
expression of p53 across the time points was milder and not
significant until 50 min after TA treatment (Figure 3C,E).
These results indicate that the TA effect on TM cells involves
cell growth regulation and proliferation in contrast to RPE
cells where TA affected no change in the expressions of c-
myc and p53 [18].
Different facets of apoptosis have been investigated: time
progression,  extrinsic  versus  intrinsic  pathways,  and
compartmentalized occurrence in individual organelles such
as the nucleus, cytosol, mitochondria, and membranes [32].
Various  microscopic  technologies,  electron  microscopy
(EM), and fluorescence microscopy that involve advanced
staining techniques reveal cell death and DNA fragmentations
[32]. The TUNEL assay is especially useful for in situ testing
for apoptosis although it is not specific for apoptosis and
shows DNA cleavage from any form of cell death and even
necrotic cells [33]. In our study, we confirmed the apoptosis
of TM cells caused by TA treatments by the TUNEL assay.
Further  study  can  be  comprehensively  performed  through
assaying for antibodies against a target of executioner caspase
and specific mediators of apoptosis.
In summary, this study is the first report on TA effects on
human TM cells. Our data suggested that the use of TA may
disrupt the TM function because of TA cytotoxicity on the TM
cells and the elevation of stress genes, c-fos and c-jun, and of
apoptosis  genes,  caspase  3  and  c-myc.  This  may  lead  to
impaired aqueous outflow through the TM and subsequently,
an elevation in IOP.
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